Erdafitinib Improves Survival in Metastatic Urothelial Cancer With FGFR Mutation

Longer median overall survival and progression-free survival seen with erdafitinib versus chemotherapy

Related Keywords

Paris ,France General ,France ,Madrid ,Spain ,Saclay ,Yohann Loriot ,European Society For Medical Oncology ,Healthday News ,New England Journal ,European Society ,Medical Oncology ,